Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Patients With Advanced Solid Tumors.

NCT02658214 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02658214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02658214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Patients With Advanced Solid Tumors.
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
April 28, 2016
Completion date
November 14, 2019
Enrollment
32 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, pancreatic ductal, carcinoma, squamous cell of head and neck, esophageal squamous cell carcinoma, esophagogastric junction neoplasms, fallopian tube neoplasms, ovarian neoplasms, peritoneal neoplasms, small cell lung carcinoma, stomach neoplasms, triple negative breast neoplasms